On December 16, 2019 Pfizer Inc. (NYSE: PFE) reported that its board of directors declared a 38-cent per share first-quarter 2020 dividend on the company’s common stock, payable March 6, 2020 to holders of the Common Stock of record at the close of business on January 31, 2020 (Press release, Pfizer, DEC 16, 2019, View Source [SID1234552401]). Pfizer increased the dividend over the fourth-quarter 2019 dividend by approximately 6 percent to 38 cents from 36 cents per share. The first-quarter 2020 cash dividend will be the 325th consecutive quarterly dividend paid by Pfizer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The dividend increase is a testament to our commitment to returning capital to shareholders and reflects our continued confidence in the business and in our pipeline," stated Dr. Albert Bourla, Pfizer chief executive officer. "It also reinforces that our focus on creating meaningful value for patients benefits all our stakeholders."
Pfizer also announced plans to host an Investor Day on Tuesday, March 31, 2020, starting at 9:00 a.m. EDT, at its global headquarters in New York, NY. Pfizer business executives and scientific leadership will provide updates on the company’s progress in advancing its R&D pipeline, specifically on product candidates with blockbuster potential that are expected to launch by 2025.
Dr. Bourla continued, "We look forward to highlighting the range of therapeutic areas and modalities in our R&D pipeline, demonstrating the growth momentum in our Biopharma businesses and providing an opportunity to meet scientific and commercial leadership in each of our core therapeutic areas. We are excited to share key aspects of our strategy to deliver sustainable, long-term growth by developing transformational medicines and vaccines that address some of the world’s greatest unmet needs in healthcare."
Invitations for in-person attendance will be distributed in coming weeks. A live webcast, including audio, video and presentation slides, will be accessible on the Pfizer’s Investor Relations website (www.pfizer.com/investors) at the time of the meeting. Interested parties unable to attend in-person or watch the live webcast will be able to view and listen to an archived copy of the webcast, which will be available on Pfizer’s Investor Relations website following the conclusion of the event.